Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comprehensive Analysis of the Key Mutation Spectrum in Bladder Cancer: Establishment and Clinical Validation of a Multiplex Mutation Detection System Based on Nucleic Acid Mass Spectrometry

NCT07424560 is registered in ClinicalTrials.gov with Zhilong Dong as lead sponsor.

NCT NCT07424560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07424560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comprehensive Analysis of the Key Mutation Spectrum in Bladder Cancer: Establishment and Clinical Validation of a Multiplex Mutation Detection System Based on Nucleic Acid Mass Spectrometry
Lead sponsor
Zhilong Dong
Phase
Observational
Overall status
Recruiting
Start date
February 25, 2026
Completion date
July 1, 2028
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy for bladder cancer, bladder cancer, bladder cancer recurrence, progression of bladder cancer